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Abstract
Vaccination strategies based on dendritic cells (DCs) armed with specific tumor antigens have been widely exploited due the prop-
erties of these immune cells in coordinating an innate and adaptive response. Here, we describe the convergent synthesis of the
bifunctional multivalent glycodendron 5, which contains nine residues of mannose for DC targeting and one residue of an immuno-
genic mimetic of a carbohydrate melanoma associated antigen. The immunological assays demonstrated that the glycodendron 5 is
able to induce human immature DC activation in terms of a phenotype expression of co-stimulatory molecules expression and
MHCII. Furthermore, DCs activated by the glycodendron 5 stimulate T lymphocytes to proliferate in a mixed lymphocytes reaction
(MLR).
Introduction
Cancer immunotherapy [1] attempts to induce a long-lasting
antitumor immunity and boost the immune response over-
coming the tumor induced immunosuppression. The immune
system, apart from very few exceptions, fails to taking an
adequate course of action against tumors. Tumor cells are
indeed poor antigen-presenting cells (APCs). Additionally, in
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neoplastic diseases the so-called “escape mechanisms” [2-4]
enable tumor cells to elude tumor-bearing immunosurveillance
of the host. A better understanding of the interactions between
cancer and immune cells may lead to more efficient
immunotherapy strategies [5,6].
In this context, the discovery of human cancer-specific antigens
[7,8] has represented a challenge for the design of tailored
cancer vaccines and it has allowed the development of antigen-
specific immunotherapy strategies. This approach offers the
advantage that the immune response induced by such antigens
should presumably be limited to tumor cells bearing antigenic
epitopes. To induce a persistent and efficient tumor immune
response and generate a pool of tumor antigen specific acti-
vated immune cells, a complex cross-talk between the innate
and the adaptive immune system is a prerequisite. In this
context, during the last two decades, dendritic cells (DCs) have
clearly been identified as essential candidates to generate thera-
peutic immunity against tumors [9-12].
DCs are the principal antigen-presenting cells (APCs) in the
immune system where they play a central role because they are
able to control self-tolerance as well as induce an effective
immune response [13,14]. They provide an essential link
between innate and adaptive immune responses [13]. They
survey the environment and, based on the typical non-clonal
recognition receptors of the innate immune system, they take up
the non-self agents and transmit the resulting information to
both B and T cells of the adaptive immune system. DCs
contribute to the peripheral tolerance and this might be deter-
mined by their functional status. Therefore, DC activation is
crucial to their function. During activation, DCs up-regulate
MHCII molecules and co-stimulatory factors, both of which are
mandatory to achieve a complete immunostimulatory function.
Since the discovery of their key role in immunogenicity in 1973
by R. Steinman [15], DCs have been identified as “nature’s
adjuvants”. Today, they are considered natural targets for
antigen delivery and therapeutic vaccination against cancer
[9,10].
Several approaches have been investigated to pulse DCs with
target antigens with the aim to induce robust and long-lasting
CD4+ and CD8+ T cell responses against tumors [9,10]. In
general, the first step of DC vaccination strategies is to arm DCs
with tumor-specific antigens. This issue has successfully been
achieved by either culturing ex vivo DCs [16,17] from bone
marrow precursors or more recently by targeting in vivo DC
receptors with specific mAbs conjugated to tumor antigens
[18,19]. In both cases, the development of a powerful DCs-
based vaccination protocol requires a careful evaluation of the
exact conditions necessary for their optimal maturation into
potent immunostimulatory APCs. In particular, a strict control
must be exercised over the form of the antigen loaded onto
DCs, the antigen quantity, the persistence, the timing and the
pathways essential for enhancing DC maturation and for
licensing the antigen-loaded DCs in the T cell zone of lymph
nodes [10].
Concerning the DCs maturation step, triggering C-type lectin
receptors (CLRs) is crucial to enhance the antitumor immunity
[10,20]. In particular, dendritic cell-specific ICAM-3 grabbing
non-integrin (DC-SIGN), which belongs to the class of CLRs, is
expressed mainly on the surface of immature DCs and plays a
crucial role in the uptake of specific pathogens. DC-SIGN is
able to bind in a Ca2+-dependent manner mannose and fucose
residues on highly glycosylated proteins expressed on
pathogens by means of its carbohydrate recognition domain
(CRD) [21]. CLRs are antigen-uptake receptors. Moreover, the
signaling pathways downstream induced by these receptors play
a pivotal role in tailoring the immune response to break tumor-
induced immunosuppression [22]. Therefore, a combination of
DC-SIGN ligands and specific tumor-associated antigens could
successfully target DCs and trigger an efficient antitumor
response.
Melanoma has long been considered a promising target for
immunotherapeutic approaches and has been a major focus of
clinical development efforts in the realm of immunotherapy
[23-25]. GM3-ganglioside 1 (Figure 1), the major glycosphin-
golipid in normal melanocytes, is overexpressed in melanoma
cells with metastatic potential [26,27]. It has been considered a
carbohydrate melanoma-associated antigen and widely investi-
gated as a key component of a potential vaccine against
melanoma disease [28].
The GM3 metabolite, named GM3-lactone 2 (Figure 1) has also
been found in melanoma cells as a minor component [29,30].
Although more immunogenic than GM3-ganglioside 1, GM3-
lactone 2 failed as an immunostimulant because under physio-
logical conditions the available amount of lactone is below the
recognition threshold and therefore scarcely effective as an
immunostimulant.
Several years ago [31], we reported on the conformational
analysis and the synthesis of thioether 3 (Figure 1), a hydrolyti-
cally stable mimetic of the GM3-lactone 2. Structurally simpler
than the native antigen, the mimetic 3 presents the folded shape
characteristics of the GM3-lactone and in addition it is stable
under physiological conditions [31]. We conjugated the mimetic
3 to the immunogenic protein KLH and demonstrated that the
corresponding KLH-glycoconjugated 4 (Figure 1) was able to
elicit in vivo antimelanoma antibodies [32].
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Figure 1: Structure of GM3-ganglioside 1, GM3-lactone 2, GM3-lactone mimetic 3, and GM3-lactone mimetic conjugated to KLH protein (4).
More recently [33], we established that the multivalent presen-
tation of this synthetic mimetic positively interferes with human
melanoma cell (A375) adhesion, migration and resistance to
apoptosis, showing a clear amplification of the biological prop-
erties of the monovalent synthetic antigen as an immunomodu-
lator as well as an anti-adhesive agent in melanoma progression.
Taking into account all these data and relying on recent results
on the use of mannose-based glycodendrons as vectors for
antigen delivery to DCs [34], we report here on the convergent
synthesis of the bifunctional multivalent glycodendron 5
(Scheme 1) and on human DC activation and related mixed-
lymphocyte reaction (MLR) induced by the antigenic glycoden-
dron 5.
Results and Discussion
Glycodendron 5 (Scheme 1) is a bifunctional compound
containing nine residues of mannose for DC targeting and one
residue of the mimetic 3 as a carbohydrate melanoma-asso-
ciated antigen. We have previously demonstrated that a glyco-
dendron bearing nine copies of the monosaccharide mannose
can be taken up by DCs in a receptor-dependent manner by
means of the lectin DC-SIGN [34]. This dendron has the
adequate size and valency to efficiently interact with this
receptor. Dendron 7 (Scheme 1), presenting an azido group at
the focal position, was synthesized as previously described [35].
This functionalization permits, in a further step, the conjuga-
tion of any molecule conveniently functionalized with an alkyne
group by a Cu(I) azide–alkyne cycloaddition (CuAAC) reac-
tion. Then, the mimetic 6 with a butyne group at the anomeric
position, which is required for the conjugation to the glycoden-
dron 7 (Scheme 1), was also prepared as already reported [33].
The synthesis of the tricyclic spiro unit of 6 was efficiently
performed relying on a totally diastereoselective inverse elec-
tron-demand [4 + 2] hetero-Diels–Alder reaction , as described
in [31].
The synthesis of compound 5 is depicted in Scheme 1. The
mimetic 6 was deprotected with sodium carbonate at room
temperature. Without further purification the resulting syrup
was conjugated with the glycodendron 7 by a CuAAC reaction
with CuSO4 as a copper source, sodium ascorbate to reduce
Cu(II) to Cu(I) in situ, and tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine (TBTA) to stabilize Cu(I). The solution was
treated with a resin (Quadrasil MP) to remove any trace of
copper that could cause interferences in the biological assays.
After purification by size exclusion chromatography by using a
LH-20 column, the bifunctional glycodendron 5  was
obtained in 86% yield and characterized by NMR and MS (elec-
trospray).
We tested in vitro human myeloid DCs (see methods) for an ac-
tivation with LPS (positive control, 1 µg/mL), the bifunctional
multivalent glycodendron 5 and 7 (negative control). Two doses
(10 µg and 50 µg) of each compound were used. Our data
showed that 5, but not 7, induces DC activation in terms of
phenotype expression of MHC class II molecules, CD80 and
CD86 co-stimulatory molecules and CD83 activation marker, as
observed with positive control (Figure 2, upper panels, one
experiment representative of three independent ones). To test
the functional activity of the differently treated DCs, we
performed on the same cells mixed lymphocytes reactions
(MLR) (see Experimental) and checked the proliferative T
lymphocyte response after allo-stimulation. As depicted in
Figure 2, DCs treated with LPS or glycodendron 5 fully stimu-
late T lymphocytes, whereas 7 does not stimulate T lympho-
cytes (Figure 2, lower panel, one experiment representative of
three independent experiments).
In the development of immunotherapy as an emerging strategy
to treat tumours, DCs are an object of great interest because
they can be used as APCs to stimulate the immune system
against a specific tumor antigen. For this purpose, DCs can be
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Scheme 1: Synthesis of the bifunctional multivalent glycodendron 5.
pulsed ex vivo with the corresponding tumor antigen. However,
this strategy is complicated and expensive, requiring the isola-
tion of patients’ DCs, the pulsing of DCs with the antigen, and
their reinsertion. Another approach envisages the targeting of
DCs in vivo by using a selective vector combined with a cargo
tumor antigen. This second strategy requires a system which
should be able to selectively target DCs in vivo. In this work,
we have shown how to combine in a single entity a manno-
sylated dendron able to selectively interact with DCs through
DC-SIGN armed with a synthetic antigen. This ditopic glyco-
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Figure 2: Upper panels: percentage of expression of dendritic cell markers (HLA-DR ECD, CD80 FITC, CD86 PE and CD83 PC5). Cell phenotypes,
expressed as the percentage of positive cells for CD80, CD86 and HLA-DR, did not change when activation took place in the presence of compound
5 (left) at 10 or 50 µg/mL compared to LPS. CD83, an activation marker, was fully expressed at the higher dose of treatment. Compound 7 did not
activate DCs when compared to LPS (right), differences between CD83 and CD86 expression are statistically significant at the two doses tested
(*p < 0.05). One experiment is representative of three independent ones. Lower panels: mixed lymphocytes reaction (MLR). Compound 5 (left) at the
dose of 10 or 50 µg/mL did not affect T lymphocyte proliferative response. As expected from the phenotype, scaffold (right) treated DCs at the dose of
10 or 50 µg/mL, significantly reduces the proliferative response (*p < 0.05). One experiment is representative of three independent ones. The analysis
was performed by an unpaired t-test indicating that the mean is statistically significant at p < 0.05.
dendron 5 demonstrated to be correctly designed to activate
dendritic cells and stimulate T cells. Biological data clearly
showed that the multivalent glycodendron 5 activates human
immature DCs, induces the expression of all co-stimulatory
molecules and MHCII, whereas the negative control 7 does not.
Indeed, DCs need both MHC II and co-stimulation properly
expressed on their surface to correctly integrate signals and acti-
vate T lymphocytes. If DCs do not sufficiently express one or
more activation factors, their function may be impaired [36].
From a functional point of view, DCs activated by 5 stimulate T
lymphocytes so that they proliferate in a classical MLR assay as
LPS-activated cells (golden standard). When we tested the scaf-
fold molecule alone (blank 7 in Figure 2) the phenotypic
expression of DCs of co-stimulatory molecules and their T cell
allo-stimulation ability was significantly impaired. Based on the
data gathered in the experiments outlined here we conclude that
the maturation/stimulation of DCs is specifically linked to the
presence of the mimetic antigen residue and not determined by
the scaffold alone.
Conclusion
Here, we reported on the convergent synthesis of the ditopic
multivalent glycodendron 5, which contains an immunogenic
mimetic of a carbohydrate melanoma associated antigen. We
demonstrated that the immunogenic carbohydrate-based
mimetic is able to induce human DCs activation if properly
presented to DCs. Moreover, we showed that this activation is
mediated by a permannosylated dendron interacting with the
surface receptor DC-SIGN. These promising and preliminary
biological results pave the way to the design of glycodendritic
structures bearing antigen cargos as a selective vector to target
APCs for stimulating immune responses. Further experiments
must be performed to verify that the DCs activated by the multi-
valent ditopic glycodendron 5 are able to induce a strong pro-
inflammatory response in vivo, thereby breaking the tolerance
toward self antigens as melanoma and bypassing the tolero-
genic environment normally established by the tumor activity.
We envisage that this kind of compounds based on multivalent
ditopic glycodendrons might be used to address the preparation
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of a synthetic vaccine against melanoma. In addition, this
strategy might be applied to other diseases in immunotherapy.
Experimental
Reagents were purchased from Sigma–Aldrich and Fluka and
were used without purification. Synthetic compounds were puri-
fied by Sephadex (LH20). Thin-layer chromatography (TLC)
was carried out with pre-coated Merck F254 silica gel plates.
Reaction completion was observed by TLC with phospho-
molibdic acid, 10% sulfuric acid in methanol or anisaldehyde as
development reagents. 1H NMR and 13C NMR spectra were
recorded on a Bruker Avance DRX 500 MHz spectrometer.
Chemical shifts (δ) for 1H NMR and 13C NMR spectra are
expressed in ppm relative to the residual solvent signal
according to the indirect referencing method of the manufac-
turer. Signals are abbreviated as s, singlet; bs, broad singlet; d,
doublet; t, triplet; q, quartet; m, multiplet. Mass spectra were
obtained with a Bruker ion-trap Esquire 6000 apparatus (ESI).
Synthesis
The preparation of compounds 6 [33] and 7 [35] was realized as
previously described.
Synthesis of Glycodendron 5
To a solution of mimetic 6 (0.006 g, 0.009 mmol) in a mixture
of methanol/THF/water (1:1:1, 1.2 mL), sodium carbonate
(46 mg, 0.40 mmol) was added. The solution was stirred at
room temperature for 2 h. After that, resin IRA-120 H+ was
added to reach pH 5. The reaction mixture was filtrated, and the
solvent evaporated. The resulting syrup, glycodendron 7
(30 mg, 0.008 mmol), CuSO4·5H2O (0.4 mg, 0.001 mmol),
TBTA (2.5 mg, 0.004 mmol) and sodium ascorbate (1 mg,
0.004 mmol) were dissolved in 0.8 mL of THF/H2O 1:1. After
2.5 h, a small amount of metal scavenger resin (Quadrasil MP)
was added, and after further 5 minutes under stirring at room
temperature the mixture was filtered on a cotton pad and the
solution was purified by size exclusion chromatography (LH-
20, MeOH 100%), furnishing 28.4 mg (86% yield, calculated
over two steps) of the glycondendron 5 as a white foam. [α]25D
+23.9 (c 1, H2O/MeOH 1:1)
1H NMR (500 MHz, D2O) δ 8.01 (s, 9H, Htriazol), 7.96 (s, 3H,
Htriazol), 7.89 (s. 1H, Htriazol), 5.09 (s, 1H, H-1gal), 4.85 (s, 9H,
H-1mann), 4.65–4.55 (m, 18H, OmannCH2CH2N), 4.56–4.45 (m,
32H, OCH2Ctriazol, OlinkerCH2CH2N, OCH2Ctriazol), 4.25–4.21
(m, 1H, H-3sial.ac), 4.08–4.04 (m, 9H, OmannCH2CH2N),
3.91–3.86 (m, 15H, OmannCH2CH2N, OlinkerCH2CH2N),
3.85–3.83 (m, 9H, H-2mann), 3.75–3.43 (m, 79H, H-6mann,
H - 3 m a n n ,  H - 5 m a n n ,  O p e n t a e r y t h r i t o l C H 2 C H 2 ,
OpentaerythritolCH2CH2, OCH2linker, CH2O1gal, H-4gal, H-5gal,
H-6gal, H-4sial.ac, H-5sial.ac, H-6sial.ac, H-7sial.ac), 3.39–3.33 (m,
24H, CH2pentaerythritol), 3.30–3.27 (m, 8H, CH2pentaerythritol),
3.09–3.04 (m, 9H, H-4mann), 2.99–2.95 (m, 4H, SCH2, Ctria-
zolCH2CH2O), 2.04–1.97 (m, 1H, H-2sial ac), 1.91–1.84 (m, 1H,
H-2sial ac); 13C NMR (125 MHz, D2O) δ 144.3 (Ctriazol), 142.4
(O-C=C-S), 125.3 (Ctriazol), 105.3 (O-C=C-S), 99.6 (C-1mann),
95.8 (C-1gal), 92.7 (C-1sial.ac.), 72.8 (C-4mann), 70.4 (C-3mann),
69.91 (C-2mann), 69.7 (CH2pentaerythritolOlinker), 68.9 (CH2O),
68 .8  (CH 2 O) ,  68 .7  (CH 2 O) ,  68 .7  (CH 2 O) ,  68 .4
(CH2pentaerythritol), 66.4 (C-5mann), 65.8 (CHO), 65.5
(OmannCH2CH2N, OCH2CH2N), 63.6 (OCH2Ctriazol), 60.7
(C-6mann), 50.0 (OmannCH2CH2N, OCH2CH2N, OCH2CH2N),
44.8 (Cpentaerythritol), 35.4 (C-2sial.ac.), 32.9 (SCH2), 35.3
(CtriazolCH2CH2); ESIMS (m/z): calcd for C166H269N39O86S,
4217; found, 2142.1 [M + 2Cl)2−, 1440.4 [M + 3Cl]3−.
Dendritic cell activation assay
Cells
DCs were generated from human monocytes of healthy donors
as previously described [37]. Briefly, anti-CD14+ monocytes
were positively sorted by magnetic microbeads (Miltenyi
Biotec). Monocytes (at the density of 1 × 106 cells/mL) were
cultured for 6 days in medium (complete RPMI, 10% FCS)
supplemented with GM-CSF (1000 U/mL, Labogen) and IL-4
(1000 U/mL, Labogen), At day 7, DCs were activated by
24 hours of incubation with LPS (1 µg/mL, Sigma–Aldrich),
compound 5 and scaffold 7 (two doses, 50 and 10 µg/mL).
DC phenotype
The DC phenotype was analyzed by flow cytometry with a
4 color EpicsXL cytometer (Beckman–Coulter), equipped with
Expo 32 software. Cell surface markers were labelled with
monoclonal antibodies (Immunotech) directed against the
following antigens (the tags are given in parentheses): CD80
(FITC), CD86 (PE), HLA-DR (ECD), CD83 (PC5). Cell vitality
was tested with propidium iodide (PI, molecular probes). The
cells were labelled in PBS with 1% FCS for 15 min at room
temperature (rt), washed twice and immediately analyzed. For
each test at least 10000 events were acquired.
Mixed lymphocyte reaction (MLR)
CD4+ T cells were negatively selected from peripheral blood
mononuclear cells (PBMCs) by using the T cell isolation kit II
from Miltenyi Biotec. Mixed lymphocyte reaction (MLR) was
performed in 96-well U bottom plates (Nunc). 1 × 105 CD4+ T
cells were incubated for 5 days in RPMI with 10% FCS
together with 1 × 104 to 1 × 103 allogeneic DCs. Experiments
were conducted in quadruplicate. At day 5, the proliferative
response was measured by the [3H]-thymidine ([3H]-Thy,
1 µCi/mL, Amersham) incorporation test. [3H]-Thy was added
for the last 8 h of incubation. Plates were then harvested
(TomtecMacIII) on glass fiber filters (Perkin Elmer), and [3H]-
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Thy uptake was measured by liquid scintillation in a Microbeta
1450 Trimux counter (Wallac). The proliferative response is
reported as a stimulation index (SI, mean cpm response/mean
cpm background).
Statistics
Data were expressed as mean + SD values. Statistical analysis
was performed by using Student’s t-test where appropriate.
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